Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (“PoC”) Agreement for Two Ophthalmic Drug Candidates
Press release Nanoform Finland Plc March 31, 2021 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (“PoC”) Agreement for Two Ophthalmic Drug Candidates Helsinki, Finland – Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Nacuity Pharmaceuticals, a Texas-based clinical stage pharmaceutical company, today announced that they have signed a Technology Proof of Concept (“PoC”) Agreement, with compensation on standard commercial terms. This will apply Nanoform’s award-winning